Design of Estradiol Loaded PLGA Nanoparticulate Formulations: A Potential Oral Delivery System for Hormone Therapy
- 1.3k Downloads
Estradiol (E2), a highly lipophilic molecule with good oral absorption but poor oral bioavailability, was incorporated into poly(lactide-co-glycolide) (PLGA) nanoparticles to improve its oral bioavailability. Nanoparticles were prepared by using polyvinyl alcohol (PVA) or didodecyldimethylammonium bromide (DMAB) as stabilizer, leading to negatively (size 410.9 ± 39.4 nm) and positively (size 148.3 ± 10.7 nm) charged particles, respectively. Both preparations showed near zero order release in vitro with about 95% drug being released within 45 and 31 days for PVA and DMAB, respectively. In situ intestinal uptake studies in male Sprague–Dawley (SD) rats showed higher uptake of DMAB stabilized nanoparticles. Following oral administration to male SD rats, E2 could be detected in blood for 7 and 2 days from DMAB and PVA stabilized nanoparticles, respectively. Histopathological examination and blood counts indicated the absence of inflammatory response. These data suggest that DMAB stabilized PLGA nanoparticles have great potential as carriers for oral delivery of estradiol.
Key Wordsabsorption blood levels DMAB estradiol nanoparticles oral administration PLGA PVA
I.B. and S.H. acknowledge NIPER Fellowships in 2003–2005. V.B. is grateful to NIPER for providing PhD Fellowship. Start-up fund from NIPER, Research grants from Royal Society of Chemistry (RSC), London, UK; Third World Academy of Science (TWAS), Italy, and Department of Science and Technology (DST), India, to M.N.V.R.K. are gratefully acknowledged. We take this opportunity to extend our sincere thanks to Orion Pharma (Finland) and Boehringer Ingelheim (Germany) for providing Estradiol and PLGA as gift samples, respectively. Thanks are due to Rahul and Dinesh for providing the technical assistance to this project.
- 1.Djakovic-Sekulic, T., Mackanski, , Persic-Janjic, N. 2001Evaluation of the predictive power of calculation procedure for molecular hydrophobicity of some estradiol derivativesJ. Chromatogr. B7666775Google Scholar
- 2.Deady, J. 2004Clinical monograph: hormone replacement therapyJ. Manag. Care Pharm.10544557Google Scholar
- 9.Hans, M. L., Lowman, A. M. 2002Biodegradable nanoparticles for drug delivery and targetingCurr. Opin. Solid State Mater. Sci.6319327Google Scholar
- 13.Kumar, M. N. V. R., Bakowsky, U., Lehr, C. M. 2004Preparation and characterization of cationic PLGA nanospheres as DNA carriersBiomaterials2517711777Google Scholar
- 14.M.-F. Ritz, P. Schmidt, and A. Mendelowitsch. 17β- Estradiol effect on the extracellular concentration of amino acids in the glutamate excitotoxicity model in the rat. Neurochemical Research 27, (2002).Google Scholar
- 21.Blau, S., Jubeh, T. T., Haupt, S. M., Rubinstein, A. 2000Drug targeting by surface cationizationCrit. Rev. Ther. Drug Carr. Syst.17425465Google Scholar
- 36.Maassen, S., Fattal, E., Muller, R., Couvreur, P. 1993Cell cultures for the assessment of toxicity and uptake of polymeric drug carriersSTP Pharma Sci.31122Google Scholar